🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to health experts.

A Global Challenge

Gonorrhoea infections are on the rise worldwide, with figures suggesting in excess of 82 million infections per year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the face of growing infection rates, escalating drug resistance and the very limited therapeutic options presently on offer.”

Medical experts are deeply concerned about the rise in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists anticipate that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is additionally indicated for UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization represents a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Data and Worldwide Availability

As per data detailed in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This puts it on an comparable level with the typical regimen, which combines a dual-drug approach. The study involved hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to make available and distribute the drug in many regions with limited resources.

Medical professionals treating patients have voiced optimism. Having a single-dose, oral treatment such as this is hailed as a "game-changer" for public health efforts. This is viewed as essential to lessen the impact of the infection for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.